【드래곤 스포츠】 보증업체놀이터추천홍보 : 프로그램제작판매제작의뢰 : 스포츠분석 : 무료스포츠중계tv : 섹시bj움짤 : 뉴스 : 안구정화

로그인

글쓰기

[IT뉴스]Curiox and Rokit Healthcare Hit Daily Limits [K-bio pulse]

온카뱅크관리자

2026-03-20 08:07:30

<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
 <section dmcf-sid="4dF8jjvmIc">
 <div contents-hash="11cefc0e56891a73df61c0b0a9d4c2f1a0fcb7c34f1197208f924c81c5ac596e" dmcf-pid="8J36AATsmA" dmcf-ptype="general">
 <div>
 This article was released as Pharm Edaily Premium Content on March 19, 2026, at 8:00 AM.
 </div>
 </div>
 [Seungkwon kim, Edaily Reporter] On the 18th, In South Korea stocks possessing innovative platform technologies showed striking strength in the pharmaceutical, bio, and healthcare sectors of the domestic stock market.
 CurioxBiosystems and RokitHealthcare both skyrocketed by approximately 30%, capturing the market's attention, while Graphy also joined the rally with a surge of around 15%.
 <figure class="figure_frm origin_fig" contents-hash="f585497abc1118ff8af587bd18799957523ca5331ff4a1fb8970c7c49d7e1676" dmcf-pid="QLUxEEYCwa" dmcf-ptype="figure">
 <img alt="CurioxBiosystems Stock Trend" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202603/20/Edaily/20260320080307985skul.png" data-org-width="690" dmcf-mid="9YT2ooCEDw" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202603/20/Edaily/20260320080307985skul.png" width="658">
 <figcaption class="txt_caption default_figure">
 CurioxBiosystems Stock Trend
 </figcaption>
 </figure>
 Curiox Biosystems Hits Upper Limit Amid 6-Day Foreign Net Buying Streak
 According to KG Zeroin MP Doctor (formerly Market Point), Curiox Biosystems closed regular trading on the 18th at 130,960 won, up about 28% from the previous trading day. In the over the counter (OTC) market, it further soared to 141,500 won, hitting the daily upper limit.
 The surge is analyzed to be driven by the materialization of partnership outcomes with global top-tier Contract Research Organizations (CROs) like Charles River, coupled with strong market expectations for massive passive fund inflows following its scheduled inclusion in the FTSE Small Cap Index in March.
 Curiox Biosystems is a company that develops and supplies automated cell washing and sample preparation equipment based on its proprietary Laminar Washing technology. Its unique technology, which allows precise cell washing without a centrifuge, is gaining traction as core infrastructure equipment in the development and manufacturing of cell therapies (such as CAR-T). Over the past two years, the company has completed its 3-product Pluto series lineup, including 'Pluto HT', 'Pluto One' and 'Pluto Code'.
 Following an 800 million won supply contract for 'Pluto HT' with UK biotech IMU Biosciences in April of last year the market anticipates large scale supply agreements with global pharmaceutical companies and CRO/CDMOs this year.
 A representative from Curiox Biosystems stated "We are further strengthening our market dominance through strategic collaborations with major global pharmaceutical companies and CROs. We will continue our aggressive expansion so that our automated solutions can establish themselves as the new global standard for cell analysis."
 Shin Min-soo, an analyst at Kiwoom Securities, analyzed, "2026 is a crucial juncture where the company will enter a full fledged growth trajectory based on its Pluto products. The software 'Pluto Code' boasts compatibility that allows installation not only on the company's own equipment but also on third party stations which will reduce the sales lead time."
 <figure class="figure_frm origin_fig" contents-hash="00a9a4e76da959cf9db7a9dfab581e8e74ddd7a03e7bb432f0f10e0315fb6ba5" dmcf-pid="ZxZ2ooCEme" dmcf-ptype="figure">
 <img alt="Rokit Healthcare stock Trend" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202603/20/Edaily/20260320080309219tbka.png" data-org-width="707" dmcf-mid="VAhBJJmjsE" dmcf-mtype="image" height="auto" src="https://img4.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202603/20/Edaily/20260320080309219tbka.png" width="658">
 <figcaption class="txt_caption default_figure">
 Rokit Healthcare stock Trend
 </figcaption>
 </figure>
 Rokit Healthcare Skyrockets 30% on Announcement of 'AI Kidney' US License-Out
 Rokit Healthcare closed trading at 128,700 won, a 30% increase from the previous trading day. Expectations of remarkable earnings growth this year, driven by the full scale expansion of the global supply chain for its flagship AI-based diabetic foot ulcer skin regeneration platform, served as the direct catalyst for the stock's surge.
 The company specializes in organ regeneration platforms combining AI and 3D bioprinting. Since its listing on the KOSDAQ in May of last year, it has surged over 550% from its initial public offering price of 11,000 won, entering the "1 Trillion Won Market Cap Club."
 Rokit Healthcare's core platforms include patient autologous tissue-based regeneration treatments for diabetic foot ulcers and an AI-based chronic kidney failure prediction solution. In the diabetic foot ulcer treatment sector, it laid the groundwork for full scale commercialization by gaining recognition for public insurance billing at a large US tertiary hospital (HOPD) in October 2025. 
 In China, it has built a foundation for global expansion by registering an original patent for a "bioprinter based on biomaterial freezing and curing methods."
 <figure class="figure_frm origin_fig" contents-hash="5ca80202381ebb6d287d2b0965240230425c104be88a2859fa8ef4c1240d2bf9" dmcf-pid="0i0PccyOs6" dmcf-ptype="figure">
 <img alt="Graphy stock trend" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202603/20/Edaily/20260320080310515pamd.png" data-org-width="680" dmcf-mid="ftGbiisAwk" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202603/20/Edaily/20260320080310515pamd.png" width="658">
 <figcaption class="txt_caption default_figure">
 Graphy stock trend
 </figcaption>
 </figure>
 Graphy Up 15% on Expectations of Global Partnerships
 Graphy also closed at 48,950 won, up approximately 15% from the previous day. Continuous market interest in expectations for global partnership expansion and high earnings growth forecasts is analyzed to be supporting the stock's upward trend. 
 In January of this year, the company renewed its 52-week high amid projections of expanded global market sales, and evaluations continue to highlight its high potential for further growth even compared to its peak.
 Graphy is a dental solutions specialist that commercialized the world's first "direct 3D printed clear aligner" by developing a special polymer material (Smap) with shape memory effects. Based on digital scan data acquired at dental clinics, orthodontic devices can be instantly printed using a 3D printer without the need for additional mold manufacturing or thermoforming processes, offering overwhelmingly superior process efficiency and cost competitiveness.
 A healthcare analyst at NH Investment &amp; Securities analyzed, "Rapid profit growth is expected as the leverage effect goes into full swing starting in 2026. Despite the sharp rise in the stock price, the company will continue to stand out in the global market based on the technological prowess of its innovative products."
 김승권 (peace@edaily.co.kr) 
 </section> 
 </div> 
 Copyright © 이데일리. 무단전재 및 재배포 금지.

댓글 총 0개

이번주 포인트랭킹

매주 일요일 밤 0시에 랭킹을 초기화합니다.

14,000상품권
23,000상품권
32,000상품권

업체홍보/구인 더보기

지식/노하우 더보기

판매의뢰 더보기

포토 더보기